TipRanks
Advertisement
Advertisement
Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel
PremiumThe FlyMeet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel
2M ago
Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action
Premium
The Fly
Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action
2M ago
Atossa Therapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Atossa Therapeutics initiated with a Buy at Rodman & Renshaw
3M ago
Jason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
PremiumRatingsJason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
4M ago
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
Premium
The Fly
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
5M ago
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
Premium
Company Announcements
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
5M ago
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
PremiumThe FlyAtossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
6M ago
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
Premium
The Fly
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
6M ago
Atossa Therapeutics announces addition of two biopharma executives to team
Premium
The Fly
Atossa Therapeutics announces addition of two biopharma executives to team
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100